Dieter Glebe Selected Research

Taurocholic Acid (Sodium Taurocholate)

1/2022	IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection.
12/2021	Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
1/2021	Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening.
1/2021	Long-term trans-inhibition of the hepatitis B and D virus receptor NTCP by taurolithocholic acid.
1/2021	Mutational Analysis of the GXXXG/A Motifs in the Human Na+/Taurocholate Co-Transporting Polypeptide NTCP on Its Bile Acid Transport Function and Hepatitis B/D Virus Receptor Function.
1/2018	Characterisation of the hepatitis B virus cross-species transmission pattern via Na+/taurocholate co-transporting polypeptides from 11 New World and Old World primate species.
1/2018	A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses.
10/2014	Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dieter Glebe Research Topics

Disease

35	Infections 01/2022 - 09/2003
22	Hepatitis B 01/2022 - 07/2005
11	Chronic Hepatitis B 01/2021 - 01/2013
6	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 10/2014
5	Persistent Infection 01/2021 - 01/2007
4	Virus Diseases (Viral Diseases) 01/2021 - 01/2014
4	Hepatitis 11/2018 - 01/2010
3	Cholestasis 01/2022 - 11/2020
3	Coinfection 01/2021 - 01/2018
3	Viremia 01/2021 - 02/2009
2	Inflammation (Inflammations) 01/2022 - 04/2016
2	Hepatitis D 11/2018 - 01/2018
2	Liver Diseases (Liver Disease) 10/2018 - 04/2016
1	Acute-Phase Reaction 01/2022
1	Carcinogenesis 01/2022
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Metabolic Diseases (Metabolic Disease) 01/2020
1	Chronic Hepatitis (Chronic Active Hepatitis) 11/2018
1	Hypersensitivity (Allergy) 09/2016
1	Liver Neoplasms (Liver Cancer) 04/2016
1	Reinfection 01/2015
1	Needlestick Injuries (Needlestick Injury) 01/2015
1	HIV Infections (HIV Infection) 12/2014
1	Fibrosis (Cirrhosis) 01/2014

Drug/Important Bio-Agent (IBA)

10	Peptides (Polypeptides)IBA 01/2022 - 07/2005
10	Membrane Proteins (Integral Membrane Proteins)IBA 11/2020 - 07/2005
9	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2021 - 08/2009
8	Taurocholic Acid (Sodium Taurocholate)IBA 01/2022 - 10/2014
7	Antiviral Agents (Antivirals)IBA 01/2021 - 07/2005
6	Surface Antigens (Surface Antigen)IBA 01/2021 - 02/2009
6	Hepatitis B e AntigensIBA 01/2021 - 08/2009
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 02/2009
5	bile acid binding proteinsIBA 01/2022 - 10/2014
5	VaccinesIBA 01/2021 - 01/2007
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2003
4	AntibodiesIBA 01/2018 - 09/2003
3	Bile Acids and Salts (Bile Acids)IBA 01/2022 - 10/2014
3	LipidsIBA 11/2020 - 06/2006
3	entecavir FDA Link 01/2016 - 01/2013
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 01/2020
2	EndocannabinoidsIBA 01/2022 - 01/2020
2	Virus ReceptorsIBA 01/2021 - 01/2021
2	Circular DNAIBA 11/2019 - 06/2006
2	sodium-bile acid cotransporterIBA 01/2019 - 10/2013
2	Monoclonal AntibodiesIBA 11/2018 - 09/2003
2	MicroRNAs (MicroRNA)IBA 10/2018 - 01/2016
2	PolymersIBA 01/2018 - 01/2008
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2018 - 10/2014
2	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 09/2016 - 07/2005
2	AntigensIBA 01/2014 - 09/2003
1	RimonabantIBA 01/2022
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2022
1	JNK Mitogen-Activated Protein KinasesIBA 01/2022
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2022
1	6-methyladenineIBA 12/2021
1	RNA (Ribonucleic Acid)IBA 12/2021
1	Engerix-BIBA 04/2021
1	Immunoglobulins (Immunoglobulin)IBA 04/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Taurolithocholic AcidIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	TriterpenesIBA 12/2020
1	betulinIBA 12/2020
1	lupaneIBA 12/2020
1	Disinfectants (Biocides)IBA 05/2020
1	4-(1'-heptylnonyl)benzenesulfonateIBA 01/2020
1	peginterferon alfa-2a (Pegasys)FDA Link 01/2020
1	Carrier Proteins (Binding Protein)IBA 01/2020
1	Interferon-alpha (Interferon Alfa)IBA 01/2020
1	Apoptosis Regulatory ProteinsIBA 10/2018
1	N-(4-aminophenethyl)spiroperidol (NAPS)IBA 01/2018
1	Arginine (L-Arginine)FDA Link 01/2018
1	REP 2055IBA 01/2018
1	REP 2139IBA 01/2018
1	Nucleic AcidsIBA 01/2018
1	Tenofovir (Viread)FDA Link 01/2018
1	EnzymesIBA 01/2018
1	CannabinoidsIBA 04/2016
1	Biological ProductsIBA 01/2016
1	OligodeoxyribonucleotidesIBA 01/2016
1	Immunologic Factors (Immunomodulators)IBA 01/2016
1	NucleotidesIBA 10/2015
1	TolerogenIBA 10/2015
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2015
1	Hepatitis B virus P proteinIBA 01/2015
1	HIV AntibodiesIBA 12/2014
1	Immunoglobulin G (IgG)IBA 12/2014
1	Hepatitis C AntibodiesIBA 12/2014
1	Anti-Idiotypic AntibodiesIBA 12/2014
1	Ezetimibe (Zetia)FDA Link 10/2014
1	Taurine FDA Link 10/2014
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 10/2014
1	Cholic AcidIBA 10/2014
1	Hydroxyproline (4 Hydroxyproline)IBA 01/2014

Therapy/Procedure

10	Therapeutics 01/2021 - 07/2005
1	Blood Transfusion (Blood Transfusions) 06/2019
1	Immunotherapy 09/2016
1	Lasers (Laser) 04/2015
1	Liver Transplantation 01/2015